{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:39:32Z","timestamp":1789850372072,"version":"4.0.1"},"reference-count":126,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.pcad.2012.07.002","type":"journal-article","created":{"date-parts":[[2012,9,23]],"date-time":"2012-09-23T12:43:36Z","timestamp":1348404216000},"page":"89-103","source":"Crossref","is-referenced-by-count":23,"title":["WHO Group 1 pulmonary arterial hypertension: Current and investigative therapies"],"prefix":"10.1016","volume":"55","author":[{"given":"Corey E.","family":"Ventetuolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Klinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2012.07.002_bb0005","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"New Engl J Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0010","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","article-title":"Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension","volume":"111","author":"Sitbon","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2012.07.002_bb0015","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1161\/CIRCULATIONAHA.109.192230","article-title":"ACCF\/AHA 2009 expert consensus document on pulmonary hypertension","volume":"119","author":"McLaughlin","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2012.07.002_bb0020","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1183\/09031936.98.12020265","article-title":"Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension","volume":"12","author":"Sitbon","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pcad.2012.07.002_bb0025","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/263663a0","article-title":"An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation","volume":"263","author":"Moncada","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.pcad.2012.07.002_bb0030","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/10409238009105464","article-title":"Prostaglandins, platelets, and atherosclerosis","volume":"7","author":"Gryglewski","year":"1980","journal-title":"CRC Crit Rev Biochem"},{"key":"10.1016\/j.pcad.2012.07.002_bb0035","doi-asserted-by":"crossref","first-page":"205S","DOI":"10.1378\/chest.114.3_Supplement.205S","article-title":"Lipid mediator dysregulation in primary pulmonary hypertension","volume":"114","author":"Christman","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0040","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","article-title":"Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension","volume":"159","author":"Tuder","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0045","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol)","volume":"112","author":"Rubin","year":"1990","journal-title":"Ann Int Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0050","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/hrt.57.3.270","article-title":"Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin)","volume":"57","author":"Jones","year":"1987","journal-title":"Br Heart J"},{"key":"10.1016\/j.pcad.2012.07.002_bb0055","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0060","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.jacc.2009.04.017","article-title":"Updated evidence-based treatment algorithm in pulmonary arterial hypertension","volume":"54","author":"Barst","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0065","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1056\/NEJM199801293380501","article-title":"Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension","volume":"338","author":"McLaughlin","year":"1998","journal-title":"New Engl J Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0070","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/1529-0131(199803)41:3<466::AID-ART13>3.0.CO;2-O","article-title":"The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis","volume":"41","author":"Menon","year":"1998","journal-title":"Arthr Rheum"},{"key":"10.1016\/j.pcad.2012.07.002_bb0075","doi-asserted-by":"crossref","first-page":"80S","DOI":"10.1378\/chest.114.1_Supplement.80S","article-title":"Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin)","volume":"114","author":"Humbert","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0080","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Int Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0085","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.3899\/jrheum.081277","article-title":"Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol","volume":"36","author":"Badesch","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0090","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.healun.2010.03.008","article-title":"Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: a national survey","volume":"29","author":"Kingman","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.pcad.2012.07.002_bb0095","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1378\/chest.11-1893","article-title":"Low incidence of catheter-related complications in patients with advanced pulmonary arterial hypertension undergoing continuous epoprostenol infusion","volume":"141","author":"Nagai","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0100","article-title":"Stability and microbiological properties of a new formulation of epoprostenol sodium when roconsituted and diluted","volume":"6","author":"Lambert","year":"2012","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.pcad.2012.07.002_bb0105","first-page":"A2499","article-title":"The PROSPECT Registry: study design, patient characteristics, and treatment patterns","volume":"185","author":"Farber","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0110","first-page":"486","article-title":"Efficacy and safety of UT-15, a prostacyclin analog, for primary pulmonary hypertension (abstract)","volume":"20","author":"McLaughlin","year":"1999","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.pcad.2012.07.002_bb0115","first-page":"A595","article-title":"Acute hemodynamic effects of 15AU81, a stable prostacyclin analogue, in severe primary pulmonary hypertension","volume":"157","author":"Gaine","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0120","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0125","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-121-6-199409150-00003","article-title":"Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin","volume":"121","author":"Barst","year":"1994","journal-title":"Ann Int Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0130","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.healun.2012.02.025","article-title":"Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension","volume":"31","author":"Sadushi-Koli\u00e7i","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.pcad.2012.07.002_bb0135","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1378\/chest.129.6.1636","article-title":"Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension","volume":"129","author":"Lang","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0140","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0735-1097(97)00187-3","article-title":"Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion","volume":"30","author":"Shapiro","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0145","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/hrt.80.2.151","article-title":"Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension","volume":"80","author":"Higenbottam","year":"1998","journal-title":"Heart"},{"key":"10.1016\/j.pcad.2012.07.002_bb0150","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1378\/chest.121.5.1561","article-title":"Transitioning from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension","volume":"121","author":"Vachi\u00e9ry","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0155","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1378\/chest.06-2118","article-title":"Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension","volume":"132","author":"Rubenfire","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0160","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00005344-200408000-00010","article-title":"Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers","author":"Laliberte","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0165","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1378\/chest.129.3.683","article-title":"Safety and efficacy of IV treprostinil for pulmonary arterial hypertension","volume":"129","author":"Tapson","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0170","unstructured":"MMWR Morb Mortal Wkly Rep. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension\u2013seven sites, United States, 2003\u20132006. 2007;56:170-2."},{"key":"10.1016\/j.pcad.2012.07.002_bb0175","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.healun.2009.09.005","article-title":"Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial","volume":"29","author":"Hiremath","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.pcad.2012.07.002_bb0180","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/0140-6736(93)92004-D","article-title":"Aerosolized prostacyclin in adult respiratory distress syndrome","volume":"342","author":"Walmrath","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2012.07.002_bb0185","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1378\/chest.124.4.1294","article-title":"Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension","volume":"124","author":"Olschewski","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0190","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"New Engl J Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0195","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.jacc.2006.06.062","article-title":"Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies","volume":"48","author":"Voswinckel","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0200","doi-asserted-by":"crossref","first-page":"149","DOI":"10.7326\/0003-4819-144-2-200601170-00026","article-title":"Inhaled treprostinil for treatment of chronic pulmonary arterial hypertension","volume":"144","author":"Voswinckel","year":"2006","journal-title":"Ann Int Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0205","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0210","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"30","author":"Members","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2012.07.002_bb0215","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1378\/chest.06-2674","article-title":"Medical therapy for pulmonary arterial hypertension","volume":"131","author":"Badesch","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0220","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.jacc.2004.02.038","article-title":"Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension","volume":"43","author":"Gali\u00e8","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0225","doi-asserted-by":"crossref","first-page":"C550","DOI":"10.1152\/ajpcell.1985.248.5.C550","article-title":"Characterization of a coronary vasoconstrictor produced by cultured endothelial cells","volume":"248","author":"Hickey","year":"1985","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0230","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A novel potent vasoconstrictor peptide produced by vascular endothelial cells","volume":"332","author":"Yanagisawa","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.pcad.2012.07.002_bb0235","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2012.07.002_bb0240","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0245","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2012.07.002_bb0250","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.amjcard.2011.03.037","article-title":"Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension","volume":"108","author":"Klinger","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0255","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.jacc.2009.07.033","article-title":"Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension","volume":"54","author":"Oudiz","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0260","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","article-title":"Ambrisentan therapy for pulmonary arterial hypertension","volume":"46","author":"Gali\u00e9","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0265","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1378\/chest.126.4.1377","article-title":"Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension","volume":"126","author":"Langleben","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0270","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1378\/chest.121.6.1860","article-title":"Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension","volume":"121","author":"Barst","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0275","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2006.01.057","article-title":"Treatment of pulmonary arterial hypertension with the selective endothelin-a receptor antagonist sitaxsentan","volume":"47","author":"Barst","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0280","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0285","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1183\/09031936.00194810","article-title":"Liver toxicity of sitaxentan in pulmonary arterial hypertension","volume":"37","author":"Gali\u00e8","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pcad.2012.07.002_bb0290","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1378\/chest.08-1028","article-title":"Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities","volume":"135","author":"McGoon","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0295","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/00912709922008380","article-title":"Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin","volume":"39","author":"Weber","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0300","first-page":"CD004434","article-title":"Endothelin receptor antagonists for pulmonary arterial hypertension","author":"Liu","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pcad.2012.07.002_bb0305","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1378\/chest.11-0404","article-title":"Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension","volume":"141","author":"Gabler","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0310","doi-asserted-by":"crossref","first-page":"9265","DOI":"10.1073\/pnas.84.24.9265","article-title":"Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide","volume":"84","author":"Ignarro","year":"1987","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.pcad.2012.07.002_bb0315","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/288373a0","article-title":"The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine","volume":"288","author":"Furchgott","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.pcad.2012.07.002_bb0320","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/(SICI)1096-9896(199807)185:3<313::AID-PATH93>3.0.CO;2-8","article-title":"High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension","volume":"185","author":"Mason","year":"1998","journal-title":"J Pathol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0325","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"New Engl J Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0330","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1172\/JCI118386","article-title":"Inhibition of cyclic 3\u2032-5\u2032-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats","volume":"97","author":"Cohen","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0335","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00395-004-0504-5","article-title":"Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells","volume":"100","author":"Tantini","year":"2005","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0340","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1161\/01.CIR.0000016641.12984.DC","article-title":"Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension","volume":"105","author":"Michelakis","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2012.07.002_bb0345","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/hc3601.096826","article-title":"Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension","volume":"104","author":"Wilkens","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2012.07.002_bb0350","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/00003246-200105000-00024","article-title":"Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension","volume":"29","author":"Ichinose","year":"2001","journal-title":"Crit Care Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0355","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1097\/00000542-200006000-00030","article-title":"Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension","volume":"92","author":"Weimann","year":"2000","journal-title":"Anesthesiol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0360","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0365","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1378\/chest.10-0969","article-title":"Long-term treatment with sildenafil citrate in pulmonary arterial hypertension","volume":"140","author":"Rubin","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0370","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2125.2010.03831.x","article-title":"Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension","volume":"71","author":"Vachiery","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0375","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00134-010-2065-4","article-title":"Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease","volume":"37","author":"Fraisse","year":"2011","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0380","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jpeds.2009.06.012","article-title":"Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension","volume":"155","author":"Steinhorn","year":"2009","journal-title":"J Pediatr"},{"key":"10.1016\/j.pcad.2012.07.002_bb0385","doi-asserted-by":"crossref","first-page":"II-167","DOI":"10.1161\/01.cir.0000087384.76615.60","article-title":"Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease","volume":"108","author":"Schulze-Neick","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2012.07.002_bb0390","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2012.07.002_bb0395","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.vph.2005.03.003","article-title":"The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: Demonstration of a ceiling effect","volume":"43","author":"Frost","year":"2005","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0400","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1164\/rccm.201101-0093OC","article-title":"Vardenafil in pulmonary arterial hypertension","volume":"183","author":"Jing","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0405","unstructured":"Consum. F. FDA updates labeling for erectile dysfunction drugs. 2005;39:3."},{"key":"10.1016\/j.pcad.2012.07.002_bb0410","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/lary.21450","article-title":"Viagra deafness \u2013 sensorineural hearing loss and phosphodiesterase-5 inhibitors","volume":"121","author":"Khan","year":"2011","journal-title":"Laryngoscope"},{"key":"10.1016\/j.pcad.2012.07.002_bb0415","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1592\/phco.30.1.112","article-title":"Sudden sensorineural hearing loss associated with vardenafil","volume":"30","author":"Snodgrass","year":"2009","journal-title":"Pharmacother"},{"key":"10.1016\/j.pcad.2012.07.002_bb0420","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0425","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1183\/09031936.06.00057906","article-title":"Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension","volume":"28","author":"Hoeper","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pcad.2012.07.002_bb0430","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2","volume":"24","author":"Humbert","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pcad.2012.07.002_bb0435","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0735-1097(03)00555-2","article-title":"Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension","volume":"42","author":"Ghofrani","year":"2003","journal-title":"J Amer Coll Cardiol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0440","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Int Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0445","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1378\/chest.114.3.787","article-title":"The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension","volume":"114","author":"Rich","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0450","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1378\/chest.120.5.1547","article-title":"Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension","volume":"120","author":"Roberts","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0455","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1378\/chest.06-1378","article-title":"Predictors of nocturnal oxygen desaturation in pulmonary arterial hypertension","volume":"131","author":"Minai","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0460","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1378\/chest.112.3.714","article-title":"The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension","volume":"112","author":"Frank","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0465","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.CIR.70.4.580","article-title":"Primary pulmonary hypertension: natural history and the importance of thrombosis","volume":"70","author":"Fuster","year":"1984","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2012.07.002_bb0470","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1183\/09031936.06.00015206","article-title":"Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review","volume":"28","author":"Johnson","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pcad.2012.07.002_bb0475","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.amjcard.2004.09.006","article-title":"New predictors of outcome in idiopathic pulmonary arterial hypertension","volume":"95","author":"Kawut","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0480","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.jacc.2004.02.029","article-title":"Cellular and molecular pathobiology of pulmonary arterial hypertension","volume":"43","author":"Humbert","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0485","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/rccm.200410-1411OC","article-title":"Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study","volume":"171","author":"Wilkins","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0490","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":"Beraprost therapy for pulmonary arterial hypertension","volume":"41","author":"Barst","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0495","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","article-title":"Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial","volume":"39","author":"Gali\u00e8","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0500","first-page":"A3360","article-title":"Clinical pharmacology and safety of beraprost sodium modified release (BPS-MR), an oral twice daily prostacyclin analogue \u2013 a phase II study","volume":"181","author":"Armstrong","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0505","first-page":"A5905","article-title":"Long-term follow-up in PAH patients dosed with beraprost sodium modified release (BPS-MR) tablets, an oral twice daily prostacyclin analogue","volume":"183","author":"Oudiz","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0510","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/0091270009351173","article-title":"Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers","volume":"50","author":"Gotzkowsky","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0515","doi-asserted-by":"crossref","first-page":"1044A","DOI":"10.1378\/chest.1212098","article-title":"FREEDOM-M: efficacy and safety of oral treprostinil diethanolamine as monotherapy in patients with pulmonary arterial hypertension","volume":"140","author":"Rubin","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0520","doi-asserted-by":"crossref","DOI":"10.1378\/chest.11-2212","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (The FREEDOM-C Study): a randomized controlled trial","author":"Tapson","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0525","first-page":"A2493","article-title":"FREEDOM-C2: efficacy and safety of oral treprostinil diethanolamine in combination with an ERA and\/or a PDE5 inhibitor in patients with pulmonary arterial hypertension","volume":"185","author":"Tapson","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0530","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1124\/jpet.108.138305","volume":"326","author":"Kuwano","year":"2008","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.pcad.2012.07.002_bb0535","doi-asserted-by":"crossref","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag, an oral, selective IP receptor agonist for the treatment of pulmonary arterial hypertension","author":"Simonneau","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pcad.2012.07.002_bb0540","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1124\/jpet.108.142976","article-title":"Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist","volume":"327","author":"Iglarz","year":"2008","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.pcad.2012.07.002_bb0545","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00228-011-1043-2","article-title":"Macitentan: entry-into-humans study with a new endothelin receptor antagonist","volume":"67","author":"Sidharta","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0550","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","article-title":"Reversal of experimental pulmonary hypertension by PDGF inhibition","volume":"115","author":"Schermuly","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0555","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1161\/CIRCULATIONAHA.108.779751","article-title":"Combined tyrosine and serine\/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling","volume":"118","author":"Klein","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2012.07.002_bb0560","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1165\/rcmb.2010-0371OC","article-title":"Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats","volume":"45","author":"Abe","year":"2011","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pcad.2012.07.002_bb0565","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMc051946","article-title":"Imatinib for the treatment of pulmonary arterial hypertension","volume":"353","author":"Ghofrani","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0570","doi-asserted-by":"crossref","first-page":"152","DOI":"10.7326\/0003-4819-145-2-200607180-00020","article-title":"Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension","volume":"145","author":"Patterson","year":"2006","journal-title":"Ann Int Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0575","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/thx.2006.064097","article-title":"Long term imatinib treatment in pulmonary arterial hypertension","volume":"61","author":"Souza","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.pcad.2012.07.002_bb0580","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1183\/09031936.00052210","article-title":"Imatinib inhibits bone marrow-derived c-kit+ cell mobilisation in hypoxic pulmonary hypertension","volume":"36","author":"Gambaryan","year":"2010","journal-title":"E ur Resp J"},{"key":"10.1016\/j.pcad.2012.07.002_bb0585","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/rccm.201001-0123OC","article-title":"Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy","volume":"182","author":"Ghofrani","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0590","doi-asserted-by":"crossref","first-page":"1045A","DOI":"10.1378\/chest.1216523","article-title":"Imatinib improves exercise capacity and hemodynamics at 24 weeks as add-on therapy in symptomatic pulmonary arterial hypertension patients: The IMPRES Study","volume":"140","author":"Hoeper","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0595","first-page":"A2495","article-title":"Imatinib safety and efficacy: interim analysis of IMPRES extension study in patients with pulmonary arterial hypertension","volume":"185","author":"Hoeper","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pcad.2012.07.002_bb0600","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib\/clinical perspective","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2012.07.002_bb0605","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1183\/09031936.00039808","article-title":"First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension","volume":"33","author":"Grimminger","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pcad.2012.07.002_bb0610","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1183\/09031936.00182909","article-title":"Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study","volume":"36","author":"Ghofrani","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pcad.2012.07.002_bb0615","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1378\/chest.109.6.1545","article-title":"Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension","volume":"109","author":"Channick","year":"1996","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0620","doi-asserted-by":"crossref","first-page":"618S","DOI":"10.1378\/chest.128.6_suppl.618S-a","article-title":"Acute cardiopulmonary hemodynamic effects of brain natriuretic peptide in patients with pulmonary arterial hypertension","volume":"128","author":"Klinger","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2012.07.002_bb0625","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/01.RES.0000157672.70560.7b","article-title":"Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells","volume":"96","author":"Zhao","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.pcad.2012.07.002_bb0630","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/eurheartj\/ehp022","article-title":"A meta-analysis of randomized controlled trials in pulmonary arterial hypertension","volume":"30","author":"Gali\u00e8","year":"2009","journal-title":"Eur Heart J"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062012001235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062012001235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T04:34:28Z","timestamp":1562214868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062012001235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":126,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0033062012001235"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2012.07.002","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}